A Look At Recursion Pharmaceuticals (RXRX) Valuation As AI Drug Discovery Progress And Earnings Expectations Gain Attention

Recursion Pharmaceuticals (RXRX) is back in focus after management detailed AI driven gains in drug discovery, including 25 new targets identified at once, as investors look ahead to an earnings ...

Why Recursion Pharmaceuticals (RXRX) Is Down 7.1% After AI-Driven Trial Acceleration And Wider EPS Loss Forecast

Earlier this week, Recursion Pharmaceuticals reported that its AI-driven Recursion OS identified 25 drug targets simultaneously and helped cut clinical trial enrollment times by up to half, ...
Seeking Alpha

Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries

Kyiv, Ukraine and Salt Lake City, UT, April 09, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced ...
Seeking Alpha

Recursion: FDA To Replace Animal Testing With AI? - A Small But Necessary Win

Recursion Pharmaceuticals' stock has been volatile, and is soaring today on news the FDA is planning on phasing out some animal testing, replacing it with AI. The company's Q4 FY24 earnings showed ...
Nasdaq

Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- The business combination of two AI-powered drug discovery and development companies, Recursion (Nasdaq: RXRX) and Exscientia has been completed, with ...
The Motley Fool

If You'd Invested $1,000 in Recursion Pharmaceuticals 4 Years Ago, Here's How Much You'd Have Today

Recursion Pharmaceuticals has significantly lagged the market since its 2021 IPO. The company's potentially revolutionary approach has yet to produce results. The stock's upside is enormous if ...
AOL

Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence (AI) Stock?

Recursion Pharmaceuticals' work could change the way that drugs are developed. Its pipeline features some exciting candidates, and it's partnering with major drugmakers. However, Recursion still needs ...
Benzinga.com

Sudden Ascent: Is Recursion Pharmaceuticals NVIDIA's AI Favorite?

The market is viewing NVIDIA's decision to keep its 7.7 million share stake in Recursion while divesting from other AI holdings as a significant strategic move. This decision indicates NVIDIA's ...
Insider Monkey

Recursion Pharmaceuticals Reports Positive Phase 1b/2 TUPELO Trial Results, Validating AI-Driven Therapy for FAP

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the AI stocks under $20 to buy now. On December 8, Recursion Pharmaceuticals announced positive Phase 1b/2 results from its ongoing TUPELO trial ...
Yahoo

Recursion Pharma's AI-powered therapy reduces polyp growth in a rare disease trial

Dec 8 (Reuters) - Recursion Pharma, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths in the colon in ...
Insider Monkey

Recursion Pharmaceuticals’ (RXRX) AI-Driven Cancer Treatment Shows Promise in Early Trials

We recently compiled a list of the 10 AI News Investors Probably Missed. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against the other AI ...
Ventureburn

Recursive Superintelligence Raises $500M Funding Round

Recursive Superintelligence raises $500M to accelerate AI innovation, signaling strong investor confidence in next-gen ...